KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Esperion Therapeutics (ESPR) Total Debt (2016 - 2026)

Esperion Therapeutics filings provide 4 years of Total Debt readings, the most recent being $152.2 million for Q4 2025.

On a quarterly basis, Total Debt rose 7.98% to $152.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $152.2 million, a 7.98% increase, with the full-year FY2025 number at $152.2 million, up 7.98% from a year prior.
Total Debt hit $152.2 million in Q4 2025 for Esperion Therapeutics, roughly flat from $151.7 million in the prior quarter.
In the past five years, Total Debt ranged from a high of $152.2 million in Q4 2025 to a low of $141.0 million in Q4 2024.